Unicycive Therapeutics Embraces Opportunity at Key Event
Unicycive Therapeutics, Inc. (NASDAQ: UNCY) is making strides in the biotechnology landscape by focusing on innovative therapies for kidney disease. Emerging from the vibrant biotechnology hub of Los Altos, California, the company is led by its Chief Executive Officer Shalabh Gupta, M.D., who will be presenting at the 24th Annual Needham Virtual Healthcare Conference. This significant presentation is set to take place soon, offering insights into the company’s latest developments.
A Window into Future Innovations
During the conference, Unicycive will provide an overview of its leading drug candidate, oxylanthanum carbonate (OLC), which is specifically designed to address hyperphosphatemia in patients with chronic kidney disease, particularly those undergoing dialysis. This therapy is pivotal, considering the growing prevalence of kidney disease globally. The progress that Unicycive has made with OLC showcases its commitment to improving patient care through science and innovation.
Understanding the Innovations of Unicycive Therapeutics
OLC has recently shown positive results in pivotal trials, which have generated optimism for both the company and the patients it aims to serve. With the New Drug Application (NDA) currently under review by the U.S. Food and Drug Administration (FDA), the anticipated Prescription Drug User Fee Act (PDUFA) Target Action Date is set for June 28, 2025. This timeline is crucial for unveiling more treatment options for individuals battling kidney-related health issues.
Intellectual Property and Its Importance
The success of OLC is not just a product of clinical trials but also stems from a robust patent portfolio protecting its composition. With exclusivity until 2031 and potential extensions beyond 2035, Unicycive is strategically positioned to sustain its innovative edge in the market. Such intellectual property shields the company’s efforts and reinforces ongoing research and development.
Second Generation Asset: UNI-494
In addition to OLC, Unicycive is contributing to kidney health with UNI-494, another significant compound that is currently in clinical development. UNI-494 is a unique chemical entity formulated to tackle acute kidney injury, providing hope for patients in critical need of therapeutic interventions. Having successfully completed a Phase 1 trial, UNI-494 is on track to offer novel solutions in treating acute renal conditions.
Staying Connected with Innovations
As Unicycive Therapeutics prepares for its conference presentation, the company encourages interested individuals and stakeholders to stay connected. The conference represents a crucial platform for disseminating information about its advancements and ongoing commitment to enhancing kidney disease management.
Investor and Media Relations
For those eager to learn more about Unicycive's progress and its impact on kidney disease treatments, communications can be directed to the Investor Contact, Kevin Gardner, at LifeSci Advisors. Media inquiries should be directed to Rachel Visi at Real Chemistry. Their efforts to keep stakeholders informed are essential as the company continues its journey to improve patient outcomes through groundbreaking therapies.
Frequently Asked Questions
1. What is Unicycive Therapeutics focusing on?
Unicycive Therapeutics is developing novel treatments for kidney diseases, including their lead drug candidate, oxylanthanum carbonate (OLC).
2. When will Unicycive present at the Needham Virtual Healthcare Conference?
The presentation is scheduled for a date soon, offering insights into the company's latest developments.
3. What are the main benefits of oxyalanthanum carbonate (OLC)?
OLC is designed to treat hyperphosphatemia in patients with chronic kidney disease, particularly beneficial for those on dialysis.
4. Why is intellectual property significant for Unicycive?
The strong patent portfolio protects Unicycive’s innovations, which supports ongoing research and enhances patient health outcomes.
5. Who can I contact for more information about Unicycive?
Investor inquiries can be directed to Kevin Gardner, while media questions should be addressed to Rachel Visi. Both roles are essential in keeping the public informed.
